The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 08, 2022

Filed:

Sep. 02, 2016
Applicant:

Memorial Sloan Kettering Cancer Center, New York, NY (US);

Inventors:

Prasad S. Adusumilli, New York, NY (US);

Michel Sadelain, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); A61K 38/20 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 38/19 (2006.01); A61K 35/28 (2015.01); A61P 35/00 (2006.01); A61K 38/17 (2006.01); A61K 38/48 (2006.01); A61K 39/395 (2006.01); C12N 9/64 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/193 (2013.01); A61K 38/2013 (2013.01); A61K 38/4873 (2013.01); A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/00118 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001114 (2018.08); A61K 39/001119 (2018.08); A61K 39/001122 (2018.08); A61K 39/001124 (2018.08); A61K 39/001126 (2018.08); A61K 39/001128 (2018.08); A61K 39/001129 (2018.08); A61K 39/001153 (2018.08); A61K 39/001157 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001174 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001195 (2018.08); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 14/70503 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/6472 (2013.01); C12Y 304/22062 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01);
Abstract

Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.


Find Patent Forward Citations

Loading…